Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer

Annals of Oncology

Volumn 18, Issue 11, 2007, Pages 1793-1798

  Meslin, F ^a   Conforti, R ^b   Mazouni, C ^c   Morel, N ^e   Tomasic, G ^b   Drusch, F ^b   Yacoub, M ^a   Sabourin, J C ^b   Grassi, J ^e   Delaloge, S ^b   Mathieu, M C ^b   Chouaib, S ^a   Andre, F ^b   Mehrpour, M ^a,d  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c TIMONE HOSPITAL   (France)

^d INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^e DIF   (France)

Author keywords

Breast cancer; Cellular prion protein; Chemotherapy; Clinical drug resistance; Estrogen receptor negative

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PRION PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYOEPITHELIUM CELL; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TISSUE MICROARRAY;

EID: 36148932985     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm406     Document Type: Article

References (31)

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2: 133-140.
2. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352: 930-942.
3. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365.
4. Thor AD, Berry DA, Budman DR et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90: 1346-1360.
5. Aas T. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811-814.
6. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8: 1107-1116.
7. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100: 10393-10398.
8. Troester MA, Hoadley KA, Sorlie T et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 2004; 64: 4218-4226.
9. Andre F, Pusztai L. Molecular classification of breast cancer implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 2006; 3: 621-632.
10. Diarra-Mehrpour M, Arrabal S, Jalil A et al. Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death. Cancer Res 2004; 64: 719-727.
11. Aguzzi A, Polymeniou M. Mammalian prion biology: One century of evolving concepts. Cell 2004; 116: 313-327.
12. Bounhar Y, Zhang Y, Goodyer CG et al. Prion protein protects human neurons against Bax-mediated apoptosis. J Biol Chem 2001; 276: 39145-39149.
13. Li A, Harris DA. Mammalian prion protein suppresses Bax-induced cell death in yeast. J Biol Chem 2005; 280: 17430-17434.
14. Roucou X, Giannopoulos PN, Zhang Y et al. Cellular prion protein inhibits proapoptotic Bax contormational change in human neurons and in breast carcinoma MCF-7 cells. Cell Death Differ 2005; 12: 783-795.
15. Roucou X, Guo Q, Zhang Y et al. Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons. J Biol Chem 2003; 278: 40877-40881.
16. Roucou X, LeBlanc AC. Cellular prion protein neuroprotective function: implications in prion diseases. J Mol Med 2005; 83: 3-11.
17. Kuwahara C. Prions prevent neuronal cell-line death. Nature 1999; 400: 225-226.
18. Senator A, Rachidi W, Lehmann S et al. Prion protein protects against DNA damage induced by paraquat in cultured cells. Free Radic Biol Med 2004; 37: 1224-1230.
19. Chiarini LB, Freitas AR, Zanata SM et al. Cellular prion protein transduces neuroprotective signals. EMBO J 2002; 21: 3317-3326.
20. Du J, Pan Y, Shi Y et al. Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR. Int J Cancer 2005; 113: 213-220.
21. Liang J, Pan YL, Ning XX et al. Overexpression of PrPC and its antiapoptosis function in gastric cancer. Tumour Biol 2006; 27: 84-91.
22. Arriagada R, Spielmann M, Koscielny S et al. Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer. Acta Oncol 2005; 44: 458-466.
23. Davies GA, Bryant AR, Reynolds JD et al. Prion diseases and the gastrointestinal tract. Can J Gastroenterol 2006; 20: 18-24.
24. Marcos Z, Bodegas ME, Sesma MP et al. Characterization of PrPc-immunoreactive cells in monkey (Macaca fascicularis) gastrointestinal tract. Ann N Y Acad Sci 2005; 1040: 387-390.
25. Jones C, Mackay A, Grigoriadis A et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: Identification of novel prognostic markers for breast cancer. Cancer Res 2004; 64: 3037-3045.
26. McLennan NF, Brennan PM, McNeill A et al. Prion protein accumulation and neuroprotection in hypoxic brain damage. Am J Pathol 2004; 165: 227-235.
27. Roucou X, Gains M, LeBlanc AC. Neuroprotective functions of prion protein. J Neurosci Res 2004; 75: 153-161.
28. Shyu WC, Lin SZ, Chiang MF et al. Overexpression of PrPC by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model. J Neurosci 2005; 25: 8967-8977.
29. Kurschner C, Morgan JI. The cellular prion protein (PrP) selectively binds to Bcl-2 in the yeast two-hybrid system. Brain Res Mol Brain Res 1995; 30: 165-168.
30. Kurschner C, Morgan JI. Analysis of interaction sites in homo- and heteromeric complexes containing Bcl-2 family members and the cellular prion protein. Brain Res Mol Brain Res 1996; 37: 249-258.
31. Rambold AS, Miesbauer M, Rapaport D et al. Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP. Mol Biol Cell 2006; 17: 3356-3368.